Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TAK
TAK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TAK News
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
22h ago
NASDAQ.COM
Takeda Reports New Data on Oveporexton for Type 1 Narcolepsy
4d ago
NASDAQ.COM
Takeda Unveils New Narcolepsy Drug Study Results
4d ago
NASDAQ.COM
Takeda Presents Oveporexton Study Results at SLEEP 2026
4d ago
Newsfilter
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
Jun 11 2026
seekingalpha
Zasocitinib Shows Superiority in Psoriasis Study
Jun 11 2026
Newsfilter
Takeda's ENTYVIO Receives FDA Acceptance for Pediatric Use
Jun 10 2026
NASDAQ.COM
Takeda Seeks FDA Approval for ENTYVIO in Pediatric Patients
Jun 09 2026
Newsfilter
Takeda Pharmaceutical Shares Enter Oversold Territory
May 22 2026
NASDAQ.COM
Innovent's IBI363 Shows Survival Benefits in Lung Cancer Treatment
May 22 2026
Yahoo Finance
Takeda Pharmaceutical Loses Antitrust Case Verdict
May 19 2026
NASDAQ.COM
Takeda Pharmaceutical Found Guilty of Delaying Generic Drug
May 18 2026
seekingalpha
Investor Sentiment Cautious as Stock Markets Decline
May 17 2026
seekingalpha
Takeda to Cut 4,500 Jobs for Cost Savings
May 14 2026
seekingalpha
Takeda's FY2025 Financial Highlights and Future Growth Strategy
May 13 2026
Newsfilter
Takeda Pharmaceutical Releases FY2026 Performance Forecast
May 13 2026
seekingalpha
Show More News
